ReviewImmunological reviews2015
Cytokine and lipid mediator networks in tuberculosis.
Review in Immunological reviews, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 101 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
101 citing papers in PubMed, 152 citations in OpenAlex.
- PGE2 displays immunosuppressive effects during human active tuberculosis.Scientific reports · 2021Trial
- Helminth Coinfection Alters Monocyte Activation, Polarization, and Function in LatentJournal of immunology (Baltimore, Md. : 1950) · 2020Trial
- Trial
- Reduced systemic and mycobacterial antigen-stimulated concentrations of IL-1β and IL-18 in tuberculous lymphadenitis.Cytokine · 2017Trial
- Protein kinase F regulates the virulence ofInfection and immunity · 2026Article
- Molecular Mechanisms of Tibetan Medicinal Sea Buckthorn in the Treatment of Pulmonary Diseases: An Integrated Analysis of Network Pharmacology and Transcriptomics.International journal of molecular sciences · 2026Article
- Phospholipase A2 Isoforms in Lung Immunity and Respiratory Infections: Potential Targets for Next-Generation Therapy.International journal of molecular sciences · 2026Review
- An updated overview of lipid-regulated immunobiology in macrophages.Acta biochimica et biophysica Sinica · 2026Review
- Longitudinal analysis of lipid mediators in post-tuberculosis lung disease identifies significant differences.PLOS global public health · 2026Article
- From clinical phenotypes to genomic signatures: machine learning integration for precision tuberculosis treatment prediction.Frontiers in bioinformatics · 2026Article
- Cell-mediated immune responses of beta-glucan on the pathogenesis of chronic tuberculosis infection.Frontiers in immunology · 2026Review
- Molecular signaling in coinfection: howFrontiers in immunology · 2026Review
- Inter-organ crosstalk in systemic inflammation: a narrative review of molecular mechanisms and pharmacological modulation in the muscle-adipose-liver axis.Frontiers in pharmacology · 2026Review
- Lesion-specific features of macrophage polarization contribute toFrontiers in immunology · 2026Article
- Protein kinase F regulates the virulence ofbioRxiv : the preprint server for biology · 2025Article
- Peripheral blood cellular dynamics during the progression of human tuberculosis.Scientific reports · 2025Article
- The regulating markers for Brucella spondylitis and tuberculous spondylitis.BMC infectious diseases · 2025Article
- A Review: Can Cytokines Induce Vascular Inflammation as a Sequela of Viral Infections?Health science reports · 2025Article
- Lessons from cross-pathogen studies: understanding the metabolic rewiring of macrophages upon infection.Frontiers in cellular and infection microbiology · 2025Review
- CD39 dynamics in tuberculosis: a potential biomarker of immune dysregulation and T cell exhaustion.Frontiers in immunology · 2025Article
41 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
A major approach for immunologic intervention in tuberculosis involves redirecting the outcome of the host immune response from the induction of disease to pathogen control. Cytokines and lipid mediators known as eicosanoids play key roles in regulating this balance and as such represent important targets for immunologic intervention. While the evidence for cytokine/eicosanoid function derives largely from the investigation of murine and zebrafish experimental infection models, clinical studies have confirmed the existence of many of the same pathways in tuberculosis patients. Here, we summarize new data that reveal important intersections between the cytokine and eicosanoid networks in the host response to mycobacteria and discuss how targeting this crosstalk can promote resistance to lethal Mycobacterium tuberculosis infection. This approach could lead to new host-directed therapies to be used either as an adjunct for improving the efficacy of standard antibiotic treatment or for the management of drug-resistant infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.